Serious adverse events · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · people with venous leg ulcers
High frequency ultrasound showed no clear difference in serious adverse events compared with no ultrasound (moderate certainty).
1 finding from 1 review
Serious adverse events · people with hepatic encephalopathy
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with collagenous colitis
Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).
1 finding from 1 review
Serious adverse events · Patients with collagenous colitis
Mesalamine showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Patients with collagenous colitis
It is very uncertain whether budesonide changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events · people with hepatorenal syndrome
Terlipressin showed no clear difference in serious adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
Serious adverse events · adults with postherpetic neuralgia
1 finding from 1 review
Serious adverse events · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher serious adverse events compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events · Adults with plantar heel pain¹
1 finding from 1 review